Journal ArticleDOI
HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS)
Chloe L. Thio,Eric C. Seaberg,Richard L. Skolasky,John P. Phair,Barbara R. Visscher,Alvaro Muñoz,David L. Thomas +6 more
TLDR
Individuals coinfected with HIV-1 and HBV, especially those with low CD4+ nadir counts, are at increased risk for liver-related mortality, underscoring the importance of prevention, identification, and comprehensive management of hepatitis B in people infected withAIDS.Citations
More filters
Journal ArticleDOI
Hepatic safety in subjects with HIV-1 and hepatitis C and/or B virus: a randomized, double-blind study of maraviroc versus placebo in combination with antiretroviral agents
Juergen K. Rockstroh,Vicente Soriano,Frank Plonski,Meena Bansal,Gerd Fätkenheuer,Catherine B. Small,David M. Asmuth,Gilles Pialoux,Geoffrey Mukwaya,Shyla Jagannatha,Jayvant Heera,Juan A. Pineda +11 more
TL;DR: The use of maraviroc does not increase hepatotoxicity in HIV-1- Infected subjects co-infected with HCV and/or HBV through 48 weeks of treatment.
Journal ArticleDOI
Evaluation of immune responses to combined hepatitis A and B vaccine in HIV-infected children and children on immunosuppressive medication.
Sanne-Meike Belderok,Gerard J.B. Sonder,Marion A J van Rossum,Annette van Dijk-Hummelman,Nico G. Hartwig,Henriette J. Scherpbier,Sibyl P. M. Geelen,Arjen G. C. L. Speksnijder,Gijs Baaten,Anneke van den Hoek +9 more
TL;DR: Both groups of children should be serologically tested for anti-HAV prior to travel to ensure protection if there is no time to await second dose of vaccine, especially for HAV in travel health and postexposure prophylactic treatment.
Journal ArticleDOI
Routine Vaccination in HIV-Infected Adults
TL;DR: The data regarding the safety, immunogenicity, and clinical efficacy of vaccines in adults infected with HIV are discussed to make an evidence-based case for increased vaccine utilization in the care of HIV-infected patients.
Journal ArticleDOI
Virology and clinical sequelae of drug-resistant HBV in HIV-HBV-coinfected patients on highly active antiretroviral therapy.
TL;DR: This review will discuss studies of drug-resistant HBV in HIV-infected persons including drug- resistant mutations that have been identified and clinical sequelae of these mutations.
References
More filters
Journal Article
Statistical methods in cancer research. Volume II--The design and analysis of cohort studies.
N. E. Breslow,N. E. Day +1 more
TL;DR: What do you do to start reading statistical methods in cancer research vol ii the design and analysis of cohort studies?
Journal ArticleDOI
The Prevalence of Hepatitis C Virus Infection in the United States, 1988 through 1994
Miriam J. Alter,Deanna Kruszon-Moran,Omana V. Nainan,Geraldine M. McQuillan,Fengxiang Gao,Linda A. Moyer,Richard A. Kaslow,Harold S. Margolis +7 more
TL;DR: The strongest factors independently associated with HCV infection were illegal drug use and high-risk sexual behavior, and poverty, having had 12 or fewer years of education, and having been divorced or separated were independently associated.
Journal ArticleDOI
Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients
Yves Benhamou,Marie Bochet,V. Di Martino,Frédéric Charlotte,F. Azria,Anne Coutellier,Michel Vidaud,François Bricaire,Pierre Opolon,Christine Katlama,Thierry Poynard +10 more
TL;DR: In coinfected patients, a low CD4 count, alcohol consumption rate, and age at HCV infection are associated with a higher liver fibrosis progression rate, while HIV seropositivity accelerates HCV‐related liver Fibrosis progression.
Journal ArticleDOI
The multicenter aids cohort study: rationale, organization, and selected characteristics of the participants
TL;DR: The Multicenter AIDS Cohort Study was designed to elucidate the natural history of the infection causing acquired immunodeficiency syndrome (AIDS), identify risk factors for occurrence and clinical expression of the virus, and establish a repository of biologic specimens for future study.
Journal ArticleDOI
Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection.
TL;DR: The data indicate that use of ritonavir may increase risk of severe hepatotoxicity, and does not support withholding protease inhibitor therapy from persons coinfected with hepatitis B or C virus.